BioSpace News Archive

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for treatment of neurodegenerative diseases, today announced that it will host a webinar on transporting biotherapeutics across the BBB on Thursday, October 15th from 1:00 p.m. to 4:00 p.m. Eastern Time.

Secura Bio, Inc. (SBI) - ( www.securabio.com ), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, today announced that it has completed the acquisition of the global rights to Copiktra® (duvelisib) for all oncology indications from Verastem, Inc. Se

The American Registry for Diagnostic Medical Sonography® (ARDMS), the internationally recognized standard in sonography credentialing, today announced it has reached an organizational milestone with its 100,000th active credentialed sonographer.

Eisai Continues MOMENTUM 2 Expanded Access Program (Study 405) for Patients Previously Prescribed Lorcaserin to Treat Dravet and Other Refractory Epilepsies [30-September-2020] WOODCLIFF LAKE, N.J. , Sept. 30, 2020 /PRNewswire/ -- Eisai Inc. announced today that, after consulting with the U.S. Food and Drug Administration (FDA), the Company has initiated a Phase 3 cli

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has filed a provisional patent for a recombinant virus binding protein (VBP) for SARS-CoV-2, the coronavirus responsible for the current COVID-19 pandemic, and is now manufacturing the VBP. Numerous studies have shown that the SARS-CoV-2’s spike

Diagnostic providers across the U.S. are overwhelmed by a high number of testing volumes – on average, 165% of their normal levels – as the country continues to utilize testing measures to control the spread of COVID-19. At a time when departments

TraceLink Inc., the leading digital platform company for the life sciences supply chain, today announced that Henry Schein, the world’s largest provider of health care solutions to office-based dental and medical practitioners, has implemented TraceLink’s verification router service (VRS) solution.

INVO Bioscience, Inc. (OTCQB: INVO) developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, announced today it has teamed up with Dr. Francisco Arredondo , MD, a respected and experienced board

Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients Award is first-ever by BARDA directed to advance development of a microbiome drug CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Vedanta Biosciences , a clinical-stage company developing a new category of therapies for immune-mediated di

From Hassenfeld Children’s Hospital at NYU Langone to Billings Clinic, and UF Health, DreaMed will integrate its remote insulin management solution into the protocols of clinics across the U.S.